MannKind announced that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes in Berlin February 22-25. Dr. Kevin Kaiserman, Vice President, Medical Affairs, Endocrine Business Unit for MannKind, will report meal challenge results from the Afrezza with Basal Combination proof-of-concept study during an oral presentation delivered on Feb 25. The data showed that subjects utilizing inhaled Technosphere Insulin lowered peak glucose levels 30 minutes faster (200 mg/dl at 60 minutes) than subjects utilizing a rapid-acting analogue with an Automated Insulin Delivery system (264 mg/dl at 90 minutes). Subjects utilizing TI also experienced a significantly lower mean PPG from 45 to 120 minutes post-meal.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNKD:
- MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
- MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
- Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
- MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
- MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease